Riskpilot← Back to searchSign inGet full accessAcrivon AB
ABActiveOrg 5591520944LundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 201813 employees
Revenue 2024
SEK 25,9M
+8% vs 2023
EBITDA margin
15.6%
+51% vs 2023
Equity ratio
1.5%
Financial strength
Net profit 2024
SEK -5,1M
-245% vs 2023
| Revenue | SEK 25,9M | +8% |
| EBITDA | SEK 4,1M | +51% |
| Net profit | SEK -5,1M | -245% |
| Total assets | SEK 42,5M | +15% |
| Equity | SEK 642K | -89% |
| Employees | 13 | — |
Legal name
Acrivon AB
Org number
5591520944
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 mars 2018
Share capital
SEK 50 000
Employees
13 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Masson, Kristina Marianne
Company purpose
Bolaget skall bedriva läkemedelsutveckling för att optimera design av kliniska prövningar inom onkologi och andra sjukdomsområden och därmed förenlig verksamhet.
Address
Lund
Email
kmasson@acrivon.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 9 596 | 13 810 | 23 945 | 25 917 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −5 277 | 1 591 | −913 | 2 691 | 4 054 |
| Depreciation & amort. | −53 | −59 | −172 | −443 | −4 636 |
| EBIT | −5 330 | 1 532 | −1 085 | 2 248 | −582 |
| Net financials | — | — | −113 | 1 281 | −7 364 |
| Profit before tax | −5 330 | 1 532 | −1 199 | 3 530 | −5 122 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −5 330 | 1 532 | −1 199 | 3 530 | −5 122 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 748 | 5 407 | 7 208 | 36 844 | 42 482 |
| Equity | 1 901 | 3 433 | 2 234 | 5 764 | 642 |
| Long-term debt | 0 | 0 | 0 | 16 569 | 36 298 |
| Short-term debt | 847 | 1 974 | 4 974 | 14 512 | 5 542 |
| Total debt | 847 | 1 974 | 4 974 | 31 081 | 41 840 |
EBITDA margin
15.6%
This company
15.8%
Market median
+1% vs market
20202024
Equity ratio
1.5%
This company
38.2%
Market median
-96% vs market
20202024
Return on equity
-797.8%
This company
18.4%
Market median
-4436% vs market
20202024
Net profit margin
-19.8%
This company
8.1%
Market median
-344% vs market
20202024
Asset turnover
0.61×
This company
1.12×
Market median
-46% vs market
20202024
Debt / equity
65.17×
This company
0.62×
Market median
-10411% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
KJ Authorized Recipient of Service | Authorized Recipient of Service | 2025 |
KM Chief Executive Officer | Chief Executive Officer | 2025 |
CA | Audit | 2022 |
| Former (1) | ||
AH Authorized Recipient of Service | Authorized Recipient of Service | 2023 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ACRIVON THERAPEUTICS INC
Acrivon AB (this company)Board members of Acrivon AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Annika Heléne Lundeslöf | Authorized Recipient of Service | 0 companies |
| Karl John Christian Karlsson | Authorized Recipient of Service | 0 companies |
| Kristina Marianne Masson | Chief Executive Officer | 0 companies |
| Curt Arne Jesper Ahlkvist | Audit | 0 companies |
| Marcin Czernik | Deputy Board Member | 0 companies |
| Peter Blume-Jensen | Board of Directors | 0 companies |